Adding Risedronate Adds No Benefit in Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
Randomised Phase II/III Study of Docetaxel With or Without Risedronate in Patients With Metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)
Eur. J. Cancer 2012 Jun 08;[EPub Ahead of Print], HJ Meulenbeld, ED van Werkhoven, JLLM Coenen, GJ Creemers, OJL Loosveld, PC de Jong, AJ ten Tije, SD Fossa, M Polee, W Gerritsen, O Dalesio, R de WitAdvanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.